SC Pembrolizumab With Berahyaluronidase Alfa Demonstrates Noninferior PK Compared to IV KEYTRUDA in Pivotal 3475A-D77 Trial April 2, 2025
Positive CHMP Opinion for the SC Formulation of Opdivo® (nivolumab) Across Multiple Solid Tumor Indications April 2, 2025
FDA Clears IND Application for Ph 1 Trial of RB-164 for Hematologic and Solid Malignancies April 2, 2025
iOncologi, Inc. Acquires TargImmune Therapeutics to Expand and Strengthen Immunotherapy Pipeline Against Solid Tumors March 18, 2025
BioCity Biopharmaceutics Announces Clinical Collaboration to Evaluate BC3195 + KEYTRUDA combination in Patients with Locally Advanced or Metastatic Solid Tumors March 18, 2025
Pierre Fabre Laboratories and RedRidge Bio Announce Drug Discovery and Co-development Partnership March 12, 2025
Medigene and EpimAb Biotherapeutics Enter into a Co-Development Partnership for TCR-Guided T Cell Engagers March 4, 2025
Swarm Oncology Ltd. and Cellex Cell Professionals GmbH Announce Strategic Partnership to Advance Swarm’s Innovative T Cell Therapies for Solid Cancers March 4, 2025
Additional Positive Data from Ph 2 Trial of NP-G2-044 in Patients with Advanced and Metastatic Solid Tumors Presented March 4, 2025
Positive Clinical Data Demonstrating Survival and Clinical Responses with triple combination of Versamune® HPV, PDS01ADC and a PD-L1 inhibitor in Recurrent/Metastatic HPV-Associated Cancers Published in JAMA Oncology March 4, 2025
All clinical studies evaluating TIDAL-01 to discontinue and further development of the program halted February 11, 2025
